

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
29 November 2007 (29.11.2007)

PCT

(10) International Publication Number  
**WO 2007/136116 A3**

(51) International Patent Classification:

C07D 309/12 (2006.01) A61K 31/351 (2006.01)  
C07D 405/10 (2006.01) A61P 3/10 (2006.01)

(21) International Application Number:

PCT/JP2007/060653

(22) International Filing Date: 18 May 2007 (18.05.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2006-139891 19 May 2006 (19.05.2006) JP  
2006-200033 21 July 2006 (21.07.2006) JP

(71) Applicant (for all designated States except US): **TAISHO PHARMACEUTICAL CO., LTD.** [JP/JP]; 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAKINUMA, Hiroyuki** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **KOBASHI, Yohei** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **HASHIMOTO, Yuko** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **OI, Takahiro** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **TAKAHASHI, Hitomi** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1,

Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **AMADA, Hideaki** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **IWATA, Yuki** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP).


(74) Agent: **YAMAGUCHI, Akiko**; YUASA and HARA, Section 206, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo, 1000004 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES



(57) Abstract: Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein  $R_1$  and  $R_2$  are the same or different and represent a hydrogen atom, a hydroxyl group, a  $C_{1-6}$  alkyl group, a  $C_{1-6}$  alkoxy group or a halogen atom,  $R_3$  is a hydrogen atom, a  $C_{1-6}$  alkyl group, a  $C_{1-6}$  alkoxy group or a halogen atom, Y is a  $C_{1-6}$  alkylene group,  $-O-(CH_2)_n-$  (n is an integer of 1 to 4) or a  $C_{2-6}$  alkenylene group, provided that when Z is  $NHC(=NH)NH_2$  or  $-NHCON(R^B)_C$ , n is not 1, Z is  $-CONHR^A$ ,  $-NHC(=NH)NH_2$  or  $-NHCON(R^B)_C$ , Formula (A) or Formula (B).





**Published:**

— *with international search report*

**(88) Date of publication of the international search report:**

13 March 2008